Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
GLP-1 agonists initially faced coverage challenges that have progressively improved
Neuroendocrine Modulation: Influences pituitary release of GH, LH, and ACTH [Kastin 1990]
These findings have positioned FOXO4-DRI as one of the most mechanistically specific senolytic peptides currently available for research purposes, distinguishing it from small-molecule senolytics that operate through broader cellular pathways
It is a triple receptor agonist, meaning it targets three appetite-regulating hormones in the body: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
But with the right trials, safety profiling, and delivery innovation, it just might be
US$ 27.73
US$ 22.72
US$ 27.65
US$ 28.28
